Otsuka Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio
Otsuka Pharmaceutical (Rockville, MD): 10 reconciled FDA prescription therapies (94.9% 2025 to 2030 cliff risk), $3.46B 2024 CMS Part D & Medicaid spend, and 96 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Rockville, MD |
| Reconciled FDA Portfolio Therapies | 10 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 94.9% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $3.46B |
| 2024 Medicare Part D Spend | $1.86B |
| 2024 Medicaid Spend | $1.60B |
| California HCAI SB 17 Filings | 96 WAC filings (max 481.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.